Truist Financial Sticks to Their Buy Rating for Cigna (CI)
Truist Financial analyst David S Macdonald maintained a Buy rating on Cigna yesterday and set a price target of $350.00.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
S Macdonald covers the Healthcare sector, focusing on stocks such as Molina Healthcare, Tenet Healthcare, and PACS Group Inc. According to TipRanks, S Macdonald has an average return of 10.6% and a 58.20% success rate on recommended stocks.
In addition to Truist Financial, Cigna also received a Buy from Deutsche Bank ‘s George Hill in a report issued on February 10. However, on February 11, Wells Fargo assigned a Hold rating to Cigna (NYSE: CI).
Based on Cigna’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $69.75 billion and a net profit of $1.87 billion. In comparison, last year the company earned a revenue of $63.69 billion and had a net profit of $739 million
Read More on CI:
Disclaimer & DisclosureReport an Issue
- Cigna: Solid Execution but Uncertain PBM Economics Support Neutral Hold Rating and $300 Target
- Cigna price target raised to $304 from $301 at Deutsche Bank
- CVS, ELV, CNC: Health Insurer Stocks Under Pressure as U.S. Expands Fraud Probe
- Subpoenas issued to eight health insurers by House panel, Axios reports
- Cigna price target raised to $375 from $340 at UBS
